# Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Source: https://onco.cc/trials/nct07723703/  
OnCo record `nct07723703` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of AMX-883 run by Amphista Therapeutics Ltd, now recruiting.

## Summary

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML is a phase 1 interventional study registered as NCT07723703 by Amphista Therapeutics Ltd, with 54 participants planned, started 2026-09-16. Conditions recorded: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Interventions recorded: AMX-883 and Posaconazole.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07723703
- Phase: 1
- Setting: A Phase 1, Open-Label, Multi-Centre Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-883 Monotherapy in Participants With Acute Myeloid Leukaemia and High-Risk Myelodysplastic Syndrome and in Combination With Anticancer Agents in Participants With Acute Myeloid Leukaemia
- Sponsor: Amphista Therapeutics Ltd
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT07723703: https://clinicaltrials.gov/study/NCT07723703

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [AMX-883](https://onco.cc/drugs/amx-883/)
- companies: [Amphista Therapeutics](https://onco.cc/companies/amphista-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07723703.json